BlackRock’s AIM ImmunoTech AIM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,990
| Closed | -$85.4K | – | 5667 |
|
|
2025
Q1 | $85.4K | Hold |
6,990
| – | – | ﹤0.01% | 4805 |
|
|
2024
Q4 | $138K | Hold |
6,990
| – | – | ﹤0.01% | 4703 |
|
|
2024
Q3 | $189K | Hold |
6,990
| – | – | ﹤0.01% | 4537 |
|
|
2024
Q2 | $260K | Hold |
6,990
| – | – | ﹤0.01% | 4497 |
|
|
2024
Q1 | $329K | Sell |
6,990
-95
| -1% | -$3.94K | ﹤0.01% | 4483 |
|
|
2023
Q4 | $311K | Buy |
7,085
+1
| +0% | +$47 | ﹤0.01% | 4535 |
|
|
2023
Q3 | $322K | Buy |
7,084
+1
| +0% | +$62 | ﹤0.01% | 4550 |
|
|
2023
Q2 | $474K | Sell |
7,083
-1,096
| -13% | -$52.9K | ﹤0.01% | 4495 |
|
|
2023
Q1 | $351K | Buy |
8,179
+34
| +0.4% | +$1.76K | ﹤0.01% | 4631 |
|
|
2022
Q4 | $254K | Buy |
8,145
+2
| +0% | +$93 | ﹤0.01% | 4788 |
|
|
2022
Q3 | $473K | Sell |
8,143
-32
| -0.4% | -$2.24K | ﹤0.01% | 4746 |
|
|
2022
Q2 | $638K | Sell |
8,175
-119
| -1% | -$11.4K | ﹤0.01% | 4692 |
|
|
2022
Q1 | $878K | Sell |
8,294
-57
| -0.7% | -$4.91K | ﹤0.01% | 4712 |
|
|
2021
Q4 | $767K | Buy |
8,351
+61
| +0.7% | +$9.43K | ﹤0.01% | 4744 |
|
|
2021
Q3 | $1.67M | Buy |
8,290
+55
| +0.7% | +$11.1K | ﹤0.01% | 4389 |
|
|
2021
Q2 | $1.77M | Sell |
8,235
-1,565
| -16% | -$335K | ﹤0.01% | 4333 |
|
|
2021
Q1 | $2.22M | Buy |
9,800
+4,687
| +92% | +$1.06M | ﹤0.01% | 4252 |
|
|
2020
Q4 | $914K | Buy |
5,113
+81
| +2% | +$16.2K | ﹤0.01% | 4233 |
|
|
2020
Q3 | $1.08M | Buy |
5,032
+271
| +6% | +$67.7K | ﹤0.01% | 4094 |
|
|
2020
Q2 | $1.18M | Buy |
4,761
+4,656
| +4,434% | +$1.13M | ﹤0.01% | 4001 |
|
|
2020
Q1 | $27K | Hold |
105
| – | – | ﹤0.01% | 4574 |
|
|
2019
Q4 | $6K | Hold |
105
| – | – | ﹤0.01% | 4787 |
|
|
2019
Q3 | $8K | Hold |
105
| – | – | ﹤0.01% | 4747 |
|
|
2019
Q2 | $46K | Hold |
105
| – | – | ﹤0.01% | 4589 |
|
|
2019
Q1 | $74K | Hold |
105
| – | – | ﹤0.01% | 4425 |
|
|
2018
Q4 | $84K | Buy |
105
+1
| +1% | +$918 | ﹤0.01% | 4388 |
|
|
2018
Q3 | $105K | Hold |
104
| – | – | ﹤0.01% | 4449 |
|
|
2018
Q2 | $146K | Hold |
104
| – | – | ﹤0.01% | 4386 |
|
|
2018
Q1 | $181K | Sell |
104
-1
| -1% | -$2.09K | ﹤0.01% | 4231 |
|
|
2017
Q4 | $160K | Hold |
105
| – | – | ﹤0.01% | 4259 |
|
|
2017
Q3 | $149K | Hold |
105
| – | – | ﹤0.01% | 4296 |
|
|
2017
Q2 | $230K | Sell |
105
-7
| -6% | -$17.3K | ﹤0.01% | 4222 |
|
|
2017
Q1 | $269K | Buy |
+112
| New | +$286K | ﹤0.01% | 4140 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3911 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3870 |
|
Other funds holding AIM
CB
HI
HI
DB
BlackRock's AIM Position: Q2 2025 in Review
BlackRock sold out of AIM ImmunoTech (AIM) in Q2 2025, closing a stake of 6,990 shares — an estimated $85.4K sold.
BlackRock first reported a position in AIM in Q1 2017 and held it in 33 quarters. The position peaked at $2.22M in Q1 2021. 12 funds tracked by Wall St. Rank hold AIM as of Q2 2025.
- BlackRock reported no remaining AIM ImmunoTech position as of Q2 2025 after selling out during the quarter.
- BlackRock sold 6,990 AIM ImmunoTech shares in Q2 2025, an estimated $85.4K.
- BlackRock first reported a position in AIM ImmunoTech in Q1 2017 and held it in 33 quarters.
- BlackRock's AIM ImmunoTech position peaked at $2.22M in Q1 2021.
- 12 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2025.
Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.